Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The New Millenium Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: wlheatmoon who wrote (420)	2/25/2000 12:25:00 PM
From: wlheatmoon	Respond to of 540

another good thing about HYSQ...no insider selling.....

To: wlheatmoon who wrote (420)	3/1/2000 11:57:00 AM
From: John Pitera	Read Replies (1) \| Respond to of 540

MIKE, with NMPS, CHRZ and ORTL/LU you must be loving life today. and we posted all that nice fundamental info on NMPS on our wild world of Stocks thread starting at post 102, Message 12180294 the next 6 or 8 posts all point out the positive developments that have been occurring for NMPS NMPS has really paid off. It shows that fundamental analysis and watching a story develop can have it's merits. ------------- Monday February 28, 7:59 am Eastern Time Company Press Release SOURCE: Matritech, Inc. Matritech's NMP179(TM) Improved Pap Smear Test Receives U.S. Patent Studies report detection of high-risk pre-cancer cases missed by present Pap smear method NEWTON, Mass., Feb. 28 /PRNewswire/ -- Matritech, Inc. (Nasdaq: NMPS - news), a company specializing in the development of products to detect, manage and screen cancer, announced today that it has been notified by the United States Patent and Trademark Office of the issuance of Patent No. 6,027,905 containing claims for the use of its NMP179(TM) Test for the identification and management of women with, or at risk for, cervical cancer. In published studies, performed in conjunction with leading cervical cancer investigators, Matritech's NMP179 Test has detected cancer as well as pre-cancer of the cervix including cases missed by the present Pap smear procedure. Claims contained in this patent protect the use of NMP179 in the United States until the year 2016. The U.S. National Institutes of Health (NIH) estimates that more than 60 million Pap smears are performed in the country each year. Although the Pap smear has significantly reduced deaths caused by cervical cancer since its adoption as a screen 50 years ago, the test fails to identify some women at risk of cancer due to its subjective interpretation. A Pap smear may contain only a small number of abnormal cells among the 50,000 to 300,000 normal cells. Thus, historical results report that 20 to 40 percent of women at risk for cervical cancer go undetected. NMP179 has the potential to improve the accuracy of Pap smears because the NMP179 antibodies cause the pre-cancerous cells to glow, making them easier to detect. Acta Cytologica, one of the world's preeminent peer-reviewed journals in the field of cytology, published a study in its November-December 1999 issue reporting the effectiveness of NMP179 in identifying women at risk for developing cervical cancer. The blinded study conducted by Brigham and Women's Hospital (Boston, Mass.) and Women and Infants' Hospital (Providence, R.I.) evaluated 261 Pap smear specimens. NMP179 detected all cases of cervical cancer and 96.7 percent of cases diagnosed as high-risk for cervical cancer